Show Notes
AI has revolutionized drug discovery by enabling scientists to process vast amounts of historical data, thus accelerating the identification of disease targets and molecule development. AI helps avoid past mistakes and improves the quality of research, making it an indispensable tool in the lab. MSD's approach to AI involves a blend of internal talent and strategic partnerships. By combining computational and web science expertise, MSD ensures that both technological and scientific endpoints are effectively addressed, says Matt Studney, SVP of Research Labs at MSD.
Topics addressed: Internal vs. External AI Development at MSD Global Data Management Challenges Generative AI's Impact on Drug Discovery Confidential AI Systems and Documentation Challenges in AI Integration Workforce Upskilling and Cultural Change Future Breakthroughs and Concerns Synthetic Data and Drug Repurposing
www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/
Youtube: https://youtu.be/pgCz-tgHaL0
More from Faces of Digital Health
Three in ten AI pilots at Sheba Medical Center never scale. Eyal Zimlichman on why, and what Europe's regulation holds back.
When prevention works, nothing happens. That's why it gets cut. Joanna Lane on financing prevention as long-term investment.
Nearly €200m, twenty years of EU health data projects. Henrique Martins on what they built and what EHDS needs next.
One ultrasound tech, four scanning rooms. NVIDIA's David Niewolny on what "augmented autonomy" asks of clinicians.
Most interoperability debates focus on exchange formats. In this discussion with Dr Nils Hellrung, medical informatician and CEO Strategy & Operations at vitagroup, Nils focuses on the need for shaping hospital IT with governance and financing.